本帖最后由 老马 于 2012-1-13 21:20 编辑
1 d1 `' d- Z+ E& S7 i! h2 M
6 H' b; d' G" n2 f爱必妥和阿瓦斯丁的比较
' E' i- I ]3 P! k. O
v2 K7 u" R- U5 X# W, X% _/ f
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/- h; @+ T; K1 `! {- f, E
2 Q& h4 i) O+ _4 ]" [
' m9 B4 B6 E/ `2 B$ F0 r& k
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/5 G3 v: Z3 b5 T7 S! c
==================================================4 [2 m6 N9 F' Y
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)+ g" g* u. f9 ^$ Q: z
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.& A) S+ B4 o6 u" T- _
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.9 [7 h* \" x' ^& H. r
|